Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Other hematologic neoplasm 1Myeloid 1Lymphoid 1Dermatologic 1

Conditions

Myelodysplastic Syndromes 27Leukemia 21Precursor Cell Lymphoblastic Leukemia-Lymphoma 19Leukemia, Myeloid, Acute 17Lymphoma 16Lymphoma, Non-Hodgkin 15Leukemia, Myeloid, Chronic-Phase 15Leukemia, Lymphocytic, Chronic, B-Cell 15Lymphoma, Follicular 14Lymphoma, B-Cell, Marginal Zone 14Anemia, Refractory, with Excess of Blasts 14Lymphoma, Mantle-Cell 13Leukemia, Myeloid, Accelerated Phase 13Myeloproliferative Disorders 12Hodgkin Disease 12Burkitt Lymphoma 12Anemia, Refractory 12Multiple Myeloma 11Lymphoma, Large B-Cell, Diffuse 10Leukemia, Myelomonocytic, Chronic 10Leukemia, Myelogenous, Chronic, BCR-ABL Positive 10Leukemia, Biphenotypic, Acute 10Dendritic Cell Sarcoma, Interdigitating 10Blast Crisis 10Recurrence 9Myelodysplastic-Myeloproliferative Diseases 9Lymphoma, Large-Cell, Immunoblastic 9Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 9Congenital Abnormalities 9Neoplasms, Plasma Cell 7

Interventions

Cyclophosphamide 23Prednisone 16N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 14Vincristine 11Doxorubicin 11Etoposide 9fludarabine phosphate 8Whole-Body Irradiation 8Mycophenolic Acid 7Lenalidomide 7Peripheral Blood Stem Cell Transplantation 6Gemcitabine 6Brentuximab Vedotin 6Azacitidine 6Alemtuzumab 6Cyclosporine 5Bortezomib 5romidepsin 4fludarabine 4Tacrolimus 4Rituximab 4Methotrexate 4Granulocyte Colony-Stimulating Factor 4Cytarabine 4pembrolizumab 3denileukin diftitox 3Transplantation 3Dexamethasone 3Carmustine 3Busulfan 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Lymphoma, T-Cell, Peripheral × Cord Blood Stem Cell Transplantation × Clear all
NCT01652014 2016-07-14

Single or Double Donor Umbilical Cord Blood Transplant in Treating Patients With High-Risk Hematologic Malignancies

Rutgers, The State University of New Jersey

Phase 2 Withdrawn
DermatologicLymphoidMyeloidOther hematologic neoplasmPlasma cell

Congenital Abnormalities, Blast Crisis, Burkitt Lymphoma, Hodgkin Disease, Immunoblastic Lymphadenopathy, Leukemia, Hairy Cell, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Multiple Myeloma, Mycosis Fungoides, Myeloproliferative Disorders, Sezary Syndrome, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Acute, Lymphoma, Large-Cell, Immunoblastic, Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral, Lymphoma, Large-Cell, Anaplastic, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Leukemia, Large Granular Lymphocytic, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, Lymphoma, Extranodal NK-T-Cell, Intraocular Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡